Table 1.

Characteristics at baseline of participants stratified by type of anti-TNF.

Variable	Level	Adalimumab	Infliximab	Overall	p
n		187	198	385
Age at first dose		37.19 [26.56–51.15]	35.25 [25.57–49.49]	35.69 [26.34–50.26]	0.466
Sex	Female	47.06% [88/187]	56.06% [111/198]	51.69% [199/385]	0.083
	Male	52.94% [99/187]	43.94% [87/198]	48.31% [186/385]
Ethnicity	White	94.12% [176/187]	94.95% [188/198]	94.55% [364/385]	0.933
	South Asian	2.14% [4/187]	2.02% [4/198]	2.08% [8/385]
	Other	3.74% [7/187]	3.03% [6/198]	3.38% [13/385]
Smoking history	Current	17.20% [32/186]	25.00% [49/196]	21.20% [81/382]	0.163
	Ex	33.33% [62/186]	28.06% [55/196]	30.63% [117/382]
	Never	49.46% [92/186]	46.94% [92/196]	48.17% [184/382]
Disease duration [years]		2.80 [0.61–9.53]	2.08 [0.53–9.52]	2.17 [0.56–9.53]	0.483
Montreal location classification	L1	31.52% [58/184]	29.44% [58/197]	30.45% [116/381]	0.956
	L2	25.54% [47/184]	26.90% [53/197]	26.25% [100/381]
	L3	42.39% [78/184]	43.15% [85/197]	42.78% [163/381]
	L4	0.54% [1/184]	0.51% [1/197]	0.52% [2/381]
Montreal behaviour classification	B1	59.24% [109/184]	63.96% [126/197]	61.68% [235/381]	0.035
	B2	35.33% [65/184]	25.38% [50/197]	30.18% [115/381]
	B3	5.43% [10/184]	10.66% [21/197]	8.14% [31/381]
Immunomodulator use at baseline	TRUE	52.94% [99/187]	48.99% [97/198]	50.91% [196/385]	0.476
Steroid use at baseline	TRUE	29.41% [55/187]	40.91% [81/198]	35.32% [136/385]	0.019
C-reactive protein [mg/L]		8.00 [4.00–19.50]	12.00 [5.00–32.00]	10.00 [5.00–24.00]	0.013
HBI score		5.00 [3.00–8.00]	6.00 [3.00–9.50]	5.00 [3.00–9.00]	0.256
Faecal calprotectin [ug/g]		307.00 [159.50–599.00]	481.00 [251.00–881.50]	365.00 [188.00–726.00]	0.001
Haemoglobin [g/L]		129.50 [120.00–140.00]	125.00 [112.00–135.00]	128.00 [116.00–137.00]	0.002
White cell count [x 109 cells per L]		7.90 [6.20–10.20]	8.56 [6.60–10.70]	8.23 [6.40–10.40]	0.166

Characteristics which are significantly different between the anti-TNFs are highlighted in bold.

TNF, tumour necrosis factor; HBI, Harvey–Bradshaw Index.